{
    "article_link": "https://doi.org/10.1038/s41586-021-04278-5",
    "data": [
        {
            "id": "data_1",
            "omics": "Genomics",
            "link": "https://ega-archive.org/",
            "format": "VCF",
            "source": "European Genome-Phenome Archive (EGA)",
            "public_id": "EGAS00001004582"
        },
        {
            "id": "data_2",
            "omics": "Transcriptomics",
            "link": "https://ega-archive.org/",
            "format": "BAM",
            "source": "European Genome-Phenome Archive (EGA)",
            "public_id": "EGAS00001004582"
        },
        {
            "id": "data_3",
            "omics": "Digital Pathology",
            "link": "",
            "format": "Whole-slide H&E images",
            "source": "Cambridge University Hospitals NHS Foundation Trust",
            "public_id": ""
        },
        {
            "id": "data_4",
            "omics": "Clinical",
            "link": "",
            "format": "Clinical Metadata",
            "source": "Cambridge University Hospitals NHS Foundation Trust",
            "public_id": ""
        }
    ],
    "analyses": [
        {
            "id": "analysis_1",
            "analysis_name": "Differential analysis",
            "analysis_data": [
                "data_2"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "residual disease"
                ]
            }
        },
        {
            "id": "analysis_2",
            "analysis_name": "Gene set enrichment analysis",
            "analysis_data": [
                "data_2",
                "MSigDB Hallmarks",
                "Reactome"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_3",
            "analysis_name": "Copy number calling",
            "analysis_data": [
                "data_1"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_4",
            "analysis_name": "Mutational signature decomposition",
            "analysis_data": [
                "data_1"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_5",
            "analysis_name": "HLA typing and neoantigen calling",
            "analysis_data": [
                "data_1",
                "data_2"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_6",
            "analysis_name": "iC10 classification",
            "analysis_data": [
                "data_1",
                "data_2"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_7",
            "analysis_name": "Multi-omic Ensemble Machine Learning Model",
            "analysis_data": [
                "data_1",
                "data_2",
                "data_3",
                "data_4"
            ],
            "label": {
                "response": [
                    "pCR",
                    "residual disease"
                ]
            }
        },
        {
            "id": "analysis_8",
            "analysis_name": "Clinical feature selection",
            "analysis_data": [
                "data_4"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "residual disease"
                ]
            }
        },
        {
            "id": "analysis_9",
            "analysis_name": "Gene set variation analysis (GSVA)",
            "analysis_data": [
                "data_2"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_10",
            "analysis_name": "T cell dysfunction and exclusion analysis (TIDE)",
            "analysis_data": [
                "data_2"
            ],
            "label": {
                "HER2_status": [
                    "HER2−"
                ]
            }
        },
        {
            "id": "analysis_11",
            "analysis_name": "Monotonic association of predictor score with RCB class",
            "analysis_data": [
                "analysis_7"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_12",
            "analysis_name": "Clonal architecture analysis",
            "analysis_data": [
                "data_1"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "residual disease"
                ]
            }
        },
        {
            "id": "analysis_13",
            "analysis_name": "Tumor mutation burden (TMB) analysis",
            "analysis_data": [
                "data_1"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_14",
            "analysis_name": "Mutational signature stratification by HER2 status",
            "analysis_data": [
                "data_1"
            ],
            "label": {
                "HER2_status": [
                    "HER2−",
                    "HER2+"
                ]
            }
        },
        {
            "id": "analysis_15",
            "analysis_name": "PCA analysis of immune cell abundance",
            "analysis_data": [
                "data_2"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        },
        {
            "id": "analysis_16",
            "analysis_name": "Precision-recall analysis",
            "analysis_data": [
                "analysis_7"
            ],
            "label": {
                "RCB class": [
                    "pCR",
                    "RCB-I",
                    "RCB-II",
                    "RCB-III"
                ]
            }
        }
    ],
    "results": [
        {
            "analysis_id": "analysis_1",
            "metrics": "Odds ratio (OR), Confidence interval (CI), P-value",
            "value": "TP53: OR=2.9, CI=1.3–6.6, P=0.01; PIK3CA: OR=2.1, CI=1.3–3.4, P=0.002",
            "features": [
                "TP53 mutations",
                "PIK3CA mutations",
                "EGFR overexpression",
                "MYC overexpression",
                "CCNE1 overexpression",
                "CDKN2A overexpression",
                "CCND1 underexpression",
                "ESR1 underexpression"
            ]
        },
        {
            "analysis_id": "analysis_2",
            "metrics": "Normalized enrichment score",
            "value": "Proliferation: P=0.0005; Immune activation: P=0.001",
            "features": [
                "Proliferation",
                "Immune activation"
            ]
        },
        {
            "analysis_id": "analysis_3",
            "metrics": "P-value",
            "value": "P=0.0002",
            "features": [
                "Copy number alterations",
                "Chromosomal instability"
            ]
        },
        {
            "analysis_id": "analysis_4",
            "metrics": "Odds ratio (OR), P-value",
            "value": "HRD: OR=1.1, P=0.006; APOBEC: OR=1.1, P=0.02",
            "features": [
                "HRD score",
                "APOBEC signature"
            ]
        },
        {
            "analysis_id": "analysis_5",
            "metrics": "Odds ratio (OR), Confidence interval (CI), P-value",
            "value": "HLA class I locus LOH: OR=3.5, CI=1.1–14.2, P<0.05; Neoantigen load: pCR median=28, residual disease median=17; 69% of LOH events targeted HLA alleles critical for neoantigen presentation",
            "features": [
                "HLA class I locus LOH",
                "Neoantigen load"
            ]
        },
        {
            "analysis_id": "analysis_6",
            "metrics": "Pearson residuals",
            "value": "iC10: overrepresented in pCR; iC3, iC7, iC8: underrepresented in pCR",
            "features": [
                "iC10 subtypes",
                "iC3 subtypes",
                "iC7 subtypes",
                "iC8 subtypes"
            ]
        },
        {
            "analysis_id": "analysis_7",
            "metrics": "AUC, Bootstrap standard deviation",
            "value": "AUC (training)=0.86, AUC (validation)=0.87; Bootstrap SD=0.05",
            "features": [
                "Age",
                "Lymphocyte density",
                "PGR expression",
                "ESR1 expression",
                "ERBB2 expression",
                "Tumor mutation burden (TMB)",
                "HRD score",
                "GGI score",
                "STAT1 score",
                "Chromosomal instability",
                "Anthracycline therapy",
                "Anti-HER2 therapy"
            ]
        },
        {
            "analysis_id": "analysis_8",
            "metrics": "AUC",
            "value": "AUC=0.70",
            "features": [
                "Tumor grade",
                "ER status",
                "HER2 status",
                "Lymph node involvement"
            ]
        },
        {
            "analysis_id": "analysis_9",
            "metrics": "Normalized enrichment score",
            "value": "GGI score: P=2×10⁻⁵; Embryonic stem-cell metagene: P=0.0001; STAT1 immune signature: P=0.00001",
            "features": [
                "GGI score",
                "Embryonic stem-cell metagene",
                "STAT1 immune signature"
            ]
        },
        {
            "analysis_id": "analysis_10",
            "metrics": "Wilcoxon rank-sum test (two-sided)",
            "value": "T cell dysfunction: P=0.006; T cell exclusion: P=0.02",
            "features": [
                "T cell dysfunction score",
                "T cell exclusion score"
            ]
        },
        {
            "analysis_id": "analysis_11",
            "metrics": "P-value",
            "value": "P=1×10⁻⁶ (validation)",
            "features": [
                "Predictor score"
            ]
        },
        {
            "analysis_id": "analysis_12",
            "metrics": "P-value",
            "value": "Subclonal mutations higher in residual disease (P=0.04, pCR vs RCB-II); clonally diverse tumors more likely to harbor resistant subclones",
            "features": [
                "Clonal mutations",
                "Subclonal mutations",
                "Clonal diversity"
            ]
        },
        {
            "analysis_id": "analysis_13",
            "metrics": "Median TMB, P-value",
            "value": "TMB pCR: 2.3, residual disease: 1.4, P=0.0005",
            "features": [
                "Tumor mutation burden (TMB)"
            ]
        },
        {
            "analysis_id": "analysis_14",
            "metrics": "Stratified odds ratio (OR), P-value by HER2 status",
            "value": "HRD: OR=1.1, P=0.006 (HER2−); APOBEC: OR=1.1, P=0.02 (HER2−)",
            "features": [
                "HRD score",
                "APOBEC signature"
            ]
        },
        {
            "analysis_id": "analysis_15",
            "metrics": "PCA score",
            "value": "Distinct clustering of immune cell types in pCR vs. residual disease",
            "features": [
                "Cytotoxic T cells",
                "Regulatory T cells",
                "Mast cells",
                "Cancer-associated fibroblasts",
                "Inhibitory NK CD56dim cells"
            ]
        },
        {
            "analysis_id": "analysis_16",
            "metrics": "Average precision, Area under precision-recall curve",
            "value": "Average precision=0.68; Area under precision-recall curve=0.67",
            "features": [
                "STAT1 immune signature",
                "GGI score",
                "Embryonic stem-cell metagene"
            ]
        }
    ]
}